CA2680039A1 — Pharmaceutical composition comprising edoxaban, an anticoagulant
Assigned to Daiichi Sankyo Co Ltd · Expires 2008-10-30 · 18y expired
What this patent protects
Disclosed is a preparation exhibiting good dissolvability over a wide pH range. Specifically disclosed is a pharmaceutical composition characterized by containing (A) N1-(5-chloropyridin-2-yl)-N2-((1S,2R,4S)-4-[(dimethylamino )carbonyl]-2-{[(5-methyl-4,5,6,7-tetrahydrothiazolo[5,…
USPTO Abstract
Disclosed is a preparation exhibiting good dissolvability over a wide pH range. Specifically disclosed is a pharmaceutical composition characterized by containing (A) N1-(5-chloropyridin-2-yl)-N2-((1S,2R,4S)-4-[(dimethylamino )carbonyl]-2-{[(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c] pyridin-2-yl)carb onyl]amino}cyclohexyl)ethanediamide represented by the formula (1) below, a pharmacologically acceptable salt thereof or a hydrate of any of them, and ( B) one or more substances selected from sugar alcohols and water-swelling ad ditives.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.